Changing trends and characteristics of peptic ulcer disease: A multicenter study from 2010 to 2019 in Korea

Table 2 Comparison of characteristics according to the etiology of peptic ulcer disease

	H. pylori-related PUD (n = 8202)	Drug-related PUD (n = 7066)	Idiopathic PUD (n = 4333)	P value	All (n = 19601)
Age ≥ 65	2043 (24.9)	3842 (54.4)	1601 (36.9)	< 0.001	7486 (38.2)
Men, n (%)	5268 (64.2)	3774 (53.4)	2747 (63.4)	< 0.001	11789 (60.1)
Gastric ulcer	5062 (61.7)	5052 (71.5)	2758 (63.7)	< 0.001	12872 (65.7)
Duodenal ulcer	3272 (39.9)	2171 (30.7)	1574 (36.3)	< 0.001	7017 (35.8)
Diagnosis, n (%)
Hypertensive disorder	928 (11.3)	2036 (28.8)	529 (12.2)	< 0.001	3493 (17.8)
Diabetes mellitus	438 (5.3)	954 (13.5)	256 (5.9)	< 0.001	1648 (8.4)
Hyperlipidemia	587 (7.2)	829 (11.7)	129 (3.0)	< 0.001	1545 (7.9)
Chronic kidney disease	173 (2.1)	604 (8.5)	123 (2.8)	< 0.001	900 (4.6)
Ischemic heart disease	483 (5.9)	1098 (15.5)	49 (1.1)	< 0.001	1630 (8.3)
Cerebrovascular disease	161 (2.0)	372 (5.3)	35 (0.8)	< 0.001	568 (2.9)
Chronic liver disease	224 (2.7)	447 (6.3)	349 (8.1)	< 0.001	1020 (5.2)
Alcoholic liver damage	164 (2.0)	253 (3.6)	234 (5.4)	< 0.001	651 (3.3)
Liver cirrhosis	175 (2.1)	381 (5.4)	325 (7.5)	< 0.001	881 (4.5)
Osteoarthritis	84 (1.0)	191 (2.7)	13 (0.4)	< 0.001	288 (1.5)
Chronic obstructive lung disease	76 (0.9)	209 (3.0)	74 (1.7)	< 0.001	359 (1.8)
Medication, n (%)
Antiplatelet agent1	634 (7.7)	1514 (21.4)	77 (1.8)	< 0.001	2225 (11.4)
Warfarin	84 (1.0)	258 (3.7)	34 (0.8)	< 0.001	376 (1.9)
DOAC	33 (0.4)	129 (1.8)	20 (0.5)	< 0.001	182 (0.9)
Steroid	690 (8.4)	1423 (20.1)	227 (5.2)	< 0.001	2340 (11.9)
Antidepressant	1188 (14.5)	2408 (34.1)	868 (20.0)	< 0.001	4464 (22.8)
Bisphosphonate	94 (1.1)	223 (3.2)	18 (0.4)	< 0.001	335 (1.7)
Immunosuppressant	125 (1.5)	275 (3.9)	35 (0.8)	< 0.001	435 (2.2)

¹Antiplatelet agents other than aspirin include clopidogrel, cilostazole, ticlopidine, triflusal, ticagrelor, and prasugrel.

PUD: Peptic ulcer disease; DOAC: Direct oral anticoagulant; H. pylori: Helicobacter pylori.